Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
April 5, 2026Cancer Research

Alpha-Particle Radiotherapy and Anti-CTLA-4 Induce Antitumor Immunity in PDAC

View Full Paper
Ask AI
Bookmark
Share

Authors

MRMarco ReisPMPoliana Camila MarinelloWBWalison Augusto da Silva Brito

Discussion

Loading...

Member takes

Overview

Demonstrates enhanced tumor regression in PDAC using alpha-particle therapy combined with anti-CTLA-4, suggesting a novel treatment approach.

Key Points

  • Investigate the combined effect of alpha-particle radiotherapy and anti-CTLA-4 on radioresistance in PDAC with mutant KRAS.
  • Used a murine model of PDAC with mtKRAS (KPC) to test treatments.
  • Administered alpha-particle radiotherapy, ATR inhibitor, and anti-CTLA-4.
  • Monitored tumor growth and regression in response to treatments.
  • Rechallenged tumor-free mice to assess systemic immunity.
  • Triple therapy led to significant tumor growth delays compared to controls (p<0.05).
  • 60% and 70% of the groups treated with Alpha DaRT + aCTLA-4 and triple therapy remained alive by day 41.
  • 40% and 50% of mice displayed complete tumor regression for over 100 days in the respective treatment groups.
  • No tumor regrowth was observed in the Alpha DaRT + aCTLA-4 group during rechallenge.

Cite This Study

Reis et al. (2026) studied this question.

synapsesocial.com/papers/69d1fdf7a79560c99a0a44c4https://doi.org/10.1158/1538-7445.am2026-4637
View Full Paper
Ask AI
Bookmark
Share